We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GSK Buys Affinivax in $3.3B Deal, Nets Two Vaccine Candidates and Novel Technology
GSK Buys Affinivax in $3.3B Deal, Nets Two Vaccine Candidates and Novel Technology
GSK announced yesterday that it is acquiring Cambridge, Mass.-based biopharma company Affinivax in a $3.3 billion deal, picking up at least two novel pneumococcal vaccine candidates and a promising vaccine technology platform.